On 6 June 2010, orphan designation (EU/3/10/751) was granted by the European Commission to Verius Limited, United Kingdom, for synthetic double-stranded siRNA oligonucleotide directed against p53 mRNA for the prevention of delayed graft function after renal transplantation.
This medicine is now known as teprasiran.
The sponsorship was transferred to Clinical Network Services (NL) B.V., Netherlands, in August 2019.
Synthetic double-stranded siRNA oligonucleotide directed against p53 mRNA (teprasiran)
|Disease / condition||
Prevention of delayed graft function after renal transplantation
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.